Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients

Current Medical Research and Opinion

Volumn 23, Issue 2, 2007, Pages 307-311

  Kwan, Jonathan T C ^a   Pratt, Raymond D ^b  

^a ST HELIER HOSPITAL   (United Kingdom)

^b SHIRE   (United States)

Author keywords

Anaemia; CKD; Epoetin delta; Erythropoietin; Predialysis

Indexed keywords

ERYTHROPOIETIN ANTIBODY; HEMOGLOBIN; NEUTRALIZING ANTIBODY; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; THROMBOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANEMIA; CELL LINE; CHRONIC DISEASE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRITINS; HEMATOCRIT; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; IRON; KIDNEY DISEASES; MALE; MIDDLE AGED; TRANSFERRIN; TREATMENT OUTCOME;

EID: 33847386390     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X162755     Document Type: Article

References (26)

1. McClellan WM. The epidemic of renal disease - what drives it and what can be done? Nephrol Dial Transplant 2006;21:1461-4
2. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504-10
3. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-10
4. Bosman DR, Winkler AS, Marsden JT, et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001;24:495-9
5. Craig KJ, Williams JD, Riley SG, et al. Anemia and diabetes in the absence of nephropathy. Diabetes Care 2005;28:1118-23
6. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548-54
7. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-9
8. Ofsthun N, Labrecque J, Lacson E, et al. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003;63:1908-14
9. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:121-32
10. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34
11. Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 2003;18(Suppl 2):ii7-12
12. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report No. 18. Invest Ophthalmol Vis Sci 1998;39:233-52
13. Obrador GT, Roberts T, St Peter WL, et al. Trends in anemia at initiation of dialysis in the United States. Kidney Int 2001;60:1875-84
14. McClellan WM, Jurkovitz C, Abramson J. The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease. Eur J Clin Invest 2005;35(Suppl 3):58-65
15. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001;98:3626-34
16. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999;14(Suppl 5):1-50
17. Valderrabano F, Horl WH, Macdougall IC, et al. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2003;18:89-100
18. Ayus JC, Go AS, Valderrabano F, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin < 10 g/dL. Kidney Int 2005;68:788-95
19. Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37:348-55
20. Hassan K, Simri W, Rubenchik I, et al. Effect of erythropoietin therapy on polyneuropathy in predialytic patients. J Nephrol 2003;16:121-5
21. Ritz E, Haxsen V. Diabetic nephropathy and anaemia. Eur J Clin Invest 2005;35(Suppl 3):66-74
22. Varki A. Loss of N-glycolylneuraminic acid in humans: mechanisms, consequences, and implications for hominid evolution. Am J Phys Anthropol 2001;(Suppl 33):54-69
23. Shahrokh Z, Flatman S, Davies M, et al. Erythropoietin produced by a human cell line has only trace levels of potentially immunogenic N-glycolylneuraminic acid residues. Haematologica 2006;91(Suppl 1):208
24. Nguyen DH, Tangvoranuntakul P, Varki A. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J Immunol 2005;175:228-36
25. Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 2002;9:376-81
26. Miwa Y, Kobayashi T, Nagasaka T, et al. Are N-glycolylneuraminic acid (Hanganutziu-Deicher) antigens important in pig-to-human xenotransplantation? Xenotransplantation 2004;11:247-53